Fortrea Appoints Robert Parks as Chief Accounting Officer
July 11 2024 - 8:00AM
Fortrea (Nasdaq: FTRE), a leading global contract research
organization (CRO), today announced that Robert “Bobby” Parks has
been appointed as chief accounting officer (CAO), responsible for
Fortrea’s accounting function, including financial reporting, risk,
controls and compliance in accordance with applicable standards,
laws and regulations.
“We are pleased to welcome Bobby to the Fortrea team, bringing
his broad and deep experience from CROs and other fast-paced
environments,” said Fortrea Chief Financial Officer Jill McConnell.
“Bobby has a track record of managing Sarbanes-Oxley Act
requirements and internal controls, including for CROs, in a
public-company setting. He is a strategic thinker who understands
our customers and our business priorities. I look forward to Bobby
making a fast start as CAO and a significant contribution to
Fortrea’s success.”
Parks brings three decades of experience to the role. Starting
his career in public accounting at Ernst & Young LLP, he served
clients in global and regulated industries, including defense and
construction. He was senior vice president and corporate controller
at Quintiles, now IQVIA, and CAO at Syneos, a leading
biopharmaceutical solutions organization. Most recently, Parks
served as CAO at SailPoint Technologies Holdings, a leader in
identity security software. He is a certified public accountant and
earned a B.S. in accounting at the University of Maryland.
Parks will join Fortrea in August, reporting to McConnell and
will serve on its Finance Leadership Team. He succeeds Amanda
Warren in this role, who will serve as an advisor to the CFO from
August through November.
About Fortrea
Fortrea (Nasdaq: FTRE) is a leading global provider of clinical
development solutions to the life sciences industry. We partner
with emerging and large biopharmaceutical, biotechnology, medical
device and diagnostic companies to drive healthcare innovation that
accelerates life changing therapies to patients. Fortrea provides
phase I-IV clinical trial management, clinical pharmacology and
consulting services. Fortrea’s solutions leverage three decades of
experience spanning more than 20 therapeutic areas, a passion for
scientific rigor, exceptional insights and a strong investigator
site network. Our talented and diverse team working in more than 90
countries is scaled to deliver focused and agile solutions to
customers globally. Learn more about how Fortrea is becoming a
transformative force from pipeline to patient at Fortrea.com and
follow us on LinkedIn and X (formerly Twitter).
Fortrea Contacts:
Hima Inguva (Investors) – 877-495-0816, hima.inguva@fortrea.com
Sue Zaranek (Media) – 919-943-5422, media@fortrea.com Kate
Dillon (Media) – 646-818-9115, kdillon@prosek.com
Fortrea (NASDAQ:FTRE)
Historical Stock Chart
From Oct 2024 to Nov 2024
Fortrea (NASDAQ:FTRE)
Historical Stock Chart
From Nov 2023 to Nov 2024